BofA lowered the firm’s price target on Neurocrine (NBIX) to $179 from $184 and keeps a Buy rating on the shares after the company reported Q4 results and guided to “more measured” Ingrezza growth in 2025. While the firm takes a more conservative view and lowers its FY25 Ingrezza sales estimate to $2.58B, it maintains its positive long-term view, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $163 from $172 at Canaccord
- Neurocrine Biosciences Reports Strong Growth in 2024
- Closing Bell Movers: Amazon slips 4% on soft Q1 outlook, capex plans
- Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93
- Neurocrine sees FY25 Ingrezza net product sales $2.5B-$2.6B